Interestingly, much evidence is emerging that TGF-β impairs NK and cytotoxic T cell immune recognition of tumors by downregulating the activating receptor NKG2D, hindering tumor removal by these cytotoxic lymphocytes [147,166]. The gene discussed is KLRK1; the disease is neoplasm.